This ASX stock has been making significant advancements lately. From receiving FDA clearance to gaining reimbursement, every news had a game changing effect on its potential growth prospects.
Veye, upon analyzing the stock, had recommended a buy on 5 August 2025, at the price of $0.355. It has more than tripled with the closing price today at $1.155.
has reported strong FY2025 results with operating revenue rising 56% to $5.9m which is driven primarily by Software-as-a-Service income of $5.7m, which is up from $3.0m in FY2024, reflecting continued global adoption of its technology. Revenue from customers climbed 87% year over year to $5.4 million, while government grants and R&D tax credits contributed in an additional $10.6 million. Initiatives are in place to generate $6.5 million in annualised savings, bringing net underlying expenditure to $35.7 million from operating expenditures of $48.2 million. Through an anticipated $6 million R&D tax credit and a $10 million strategic investment from Pro Medicus, the company ended the year with a proforma cash balance of $16.9 million, placing it in a strong position to grow its revenue and hit important targets. In FY2025, 4DMedical achieved strong growth in global adoption, with SaaS products now delivered at 388 sites, up 60% from 242 sites in June 2024. In addition, scan volumes were increased, rising 35% QoQ to over 74,000 scans in Q4 alone. 194,789 structural and functional scans were finished for the entire year, suggesting high demand for a variety of products, such as LDAiTM, LDAfTM, SeleCTTM, IQ-UIPTM, and strategic non-revenue scans for market seeding.
4DMedical has executed a five-year Reseller Agreement with Philips which is marking a strategic partnership to expand access to its SaaS suite, including XV Technology , in the U.S. market. Philips will have non-exclusive distribution rights for commercial clients and exclusive distribution rights for U.S. government clients like the Department of Defence and Veterans Affairs. Significant growth opportunities are being driven by the training of more than 200 Philips employees and the launch of products in its catalogue. On 1 September, 4DMedical announced CT: VQ™, a breakthrough in ventilation-perfusion imaging, delivering the world’s first quantitative VQ data and visualisations from routine CT scans without the need for radiotracers or contrast agents. It eliminates the complexity, regulatory limitations, and artefacts present in nuclear VQ imaging while generating high-resolution ventilation and perfusion maps by measuring regional changes in lung tissue motion and density. Through its seamless integration into current CT protocols, CT: VQTM makes use of the more than 14,500 CT scanners in the United States, providing advanced diagnostic access even to remote facilities without nuclear medicine infrastructure. CT: VQ™ represents a market opportunity exceeding USD $1.1 billion domestically and USD $2.6 billion globally, with over one million nuclear VQ scans performed annually in the U.S. at an average reimbursement of USD $1,150. Its ability to replace traditional VQ scans while enhancing workflows, accessibility, and patient outcomes has been demonstrated by extensive validation, which shows that it has diagnostic accuracy similar to SPECT.
(Source: Company Announcements)
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
